Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$115,554 | -$135,893 | -$62,091 | -$13,827 |
| Dep. & Amort. | $1,225 | $877 | $325 | $312 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $27,818 | $19,830 | $13,460 | $8,455 |
| Change in WC | $3,844 | $306 | -$951 | $1,372 |
| Other Non-Cash | -$360 | -$2,613 | $227 | $7,436 |
| Operating Cash Flow | -$83,027 | -$117,493 | -$49,030 | $3,748 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,567 | -$1,502 | -$506 | -$586 |
| Net Acquisitions | $0 | $0 | $144,123 | $0 |
| Inv. Purchases | -$265,628 | -$28,664 | -$149,438 | $0 |
| Inv. Sales/Matur. | $73,000 | $174,770 | $5,315 | $0 |
| Other Inv. Act. | -$5,000 | -$4,000 | -$144,123 | $0 |
| Investing Cash Flow | -$199,195 | $140,604 | -$144,629 | -$586 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $39,600 | $10,000 | $19,125 | $0 |
| Stock Issued | $115,056 | $120,176 | $74,862 | $21 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $154,656 | $130,176 | $93,987 | $21 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$127,566 | $153,287 | -$99,672 | $3,183 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $224,947 | $71,660 | $171,332 | $168,149 |
| End Cash | $97,381 | $224,947 | $71,660 | $171,332 |
| Free Cash Flow | -$84,594 | -$122,995 | -$49,536 | $3,162 |